Hayfin Expects Private-Debt M&A; BI on Ozempic Risks

Hayfin Expects Private-Debt M&A; BI on Ozempic Risks

0 Umsagnir
0
Episode
51 of 144
Lengd
33Mín.
Tungumál
enska
Gerð
Flokkur
Viðskiptabækur

Private-debt firms are set to consolidate as larger companies dominate deal flow, according to Marc Chowrimootoo, portfolio manager at Hayfin Capital Management. “We’re seeing a concentration within fewer hands,” Chowrimootoo tells Bloomberg News’ Lisa Lee and James Crombie and Bloomberg Intelligence’s Julie Hung in the latest Credit Edge podcast. “That trend is going to continue.” He identifies debt refinancing as the big opportunity for private lenders in 2024. Hayfin likes the health-care and software sectors, while avoiding smaller borrowers that are struggling with higher rates. In addition, BI’s Hung weighs the impact on food and drink companies of weight-loss drugs like Ozempic.

See omnystudio.com/listener for privacy information.


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for Hayfin Expects Private-Debt M&A; BI on Ozempic Risks

Other podcasts you might like ...